MedPath

ARADIGM CORPORATION

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

Phase 3
Completed
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
First Posted Date
2014-04-04
Last Posted Date
2021-03-26
Lead Sponsor
Aradigm Corporation
Target Recruit Count
304
Registration Number
NCT02104245

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

Phase 3
Completed
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
First Posted Date
2012-01-23
Last Posted Date
2021-03-26
Lead Sponsor
Aradigm Corporation
Target Recruit Count
278
Registration Number
NCT01515007

Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa

Withdrawn
Conditions
Cystic Fibrosis
Interventions
First Posted Date
2010-03-23
Last Posted Date
2023-11-22
Lead Sponsor
Aradigm Corporation
Registration Number
NCT01090908

Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

Phase 2
Completed
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
First Posted Date
2009-04-29
Last Posted Date
2017-01-25
Lead Sponsor
Aradigm Corporation
Target Recruit Count
95
Registration Number
NCT00889967
Locations
🇬🇧

"1st Floor, Nuffield House, B15 2TH, Birmingham, Britain, United Kingdom

🇬🇧

"Ground Floor, Tower Block, Lisburn Road, Belfast, Britain, United Kingdom

🇬🇧

"Stott Lane, Salford, United Kingdom

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath